Using AMH and FSH in combination with hormonal therapy and menstrual pattern allowed for better estimation of ovarian function in this study and follows expert recommendations for AYA cancer survivors.24,58 Other studies mainly used treatment gonadotoxicity to estimate impaired fertility and only a few included biomarkers, most often limited to FSH.10,11,12 Another strength was a sufficient population to assess associations with both under- and overestimation of risk. Here, AMH is linked to cancer.